Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing

- Antibody Cocktail Demonstrates Comparable Head-to-Head Potency to GSK/Vir’s Sotrovimab in Live Virus Neutralization Assay Against Omicron (B.1.1.529) -

- IMM20253 Antibody Exhibits a Novel Mechanism of Action -

EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).

“We are pleased to report that, as predicted, Immunome’s antibody cocktail retained activity against Omicron in live virus testing,” said Purnanand Sarma, PhD, President & CEO of Immunome. “In recent weeks, there has been a significant reduction in the number of antibody therapeutics under Emergency Use Authorization that are active against Omicron, demonstrating a clear, immediate need for continued advancement of novel therapeutic approaches. Immunome’s cocktail includes an ACE2 independent mechanism of anti-viral activity, which offers a differentiated way to fight SARS-CoV-2 variants that we believe is less susceptible to variant drift than other treatments.”

Immunome shared the following updates regarding the effectiveness of the antibody cocktail:

• IMM20253 exhibits a novel mechanism of action not reported with any other Emergency Use Authorization (EUA) antibodies by promoting a proteolytic cleavage of the portion of the spike protein needed for ACE2 binding, thus reducing the ability of the virus to infect host cells. In addition, IMM20253 induces potent non-neutralizing activity via phagocytosis. The IMM20253 epitope appears to be broadly conserved across other betacoronaviruses, including SARS-CoV-1. When tested in both laboratories, IMM20253 retained similar potency against Omicron compared to reference strains.
• A head-to-head test using live virus was performed at Boston University’s National Emerging Infectious Diseases Laboratories to evaluate relative neutralization potency. In this assay, Immunome’s IMM20253/IMM20184 combination neutralized the Omicron variant within 3.5-fold potency (IC50 of 27 nM) compared to S309 (IC50 of 8 nM), the preclinical version of sotrovimab (GSK/Vir). According to the FDA’s EUA Fact Sheet for sotrovimab,